Relationship of Soluble Klotho and Early Stage of Diabetic Nephropathy: A Systematic Review and Meta-Analysis

Caihong Xin1,2†, Xin Sun3†, Zheng Li1 and Tianshu Gao1*

1 Liaoning University of Traditional Chinese Medicine, Shenyang, China, 2 Department of Endocrinology and Metabolism, Fourth People’s Hospital of Shenyang, Shenyang, China, 3 Department of Endocrinology and Metabolism, First Affiliated Hospital of Soochow University, Suzhou, China

Background: Diabetic nephropathy (DN) is a chronic microvascular complication caused by long-term hyperglycemia in patients with diabetes and an important cause of end-stage renal disease. Although some studies have shown that soluble Klotho (sKlotho) levels of patients with DN are lower than those without DN, in the early stage of patients with DN with normal renal function and albuminuria, the change in sKlotho is still controversial.

Aim: This meta-analysis was conducted to statistically evaluate sKlotho levels in patients with DN.

Methods: We searched the following electronic databases: Web of Science, Embase, PubMed, Google Scholar, and China National Knowledge Infrastructure (CNKI). The following search terms were used for the title or abstract: “diabetic kidney disease”, “diabetic nephropathy”, OR “DN” in combination with “Klotho”. The meta-analysis results were presented as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs).

Results: Fourteen articles were included in the meta-analysis. In our meta-analysis, we found that the sKlotho level in patients with DN was significantly lower than that in patients without DN (SMD: -1.52, 95% CI [-2.24, -0.80]), and it was also significantly lower in the early stage of patients with DN with normal renal function and albuminuria, the change in sKlotho is still controversial.

Conclusions: This systematic review was the first to evaluate the relationship between sKlotho levels and DN. The sKlotho level was significantly lower in the early stages of DN, indicating that sKlotho might be a new biomarker of DN in the future.

Keywords: Klotho, diabetic nephropathy, DN, meta-analyses, Systematic (Literature) Review
INTRODUCTION

Diabetic nephropathy (DN) is a chronic microvascular complication caused by long-term hyperglycemia in patients with diabetes and an important cause of chronic kidney disease (CKD). The pathogenesis of DN is complex. It is associated with hyperglycemia and insulin resistance in patients with diabetes. It has also been associated with abnormal lipid metabolism, inflammation, and oxidative stress (1, 2). The onset of DN is insidious, and there are often no obvious clinical manifestations in its early stages. Once it enters the clinical stage of nephropathy, renal lesions will be irreversible, which will delay the treatment of the disease. Therefore, early diagnosis and treatment are effective for treating DN (3). Microalbuminuria is considered to be the most common early manifestation of DN. However, microalbuminuria is often intermittent and fluctuating, and the early stage of nephropathy is often not accompanied by obvious symptoms, which can easily be ignored and missed (4). Therefore, new biomarkers are urgently required to assist in the early diagnosis of DN.

Klotho is a protein with anti-aging activity discovered by Japanese scientists in spontaneously hypertensive rats in 1997 (5). The Klotho gene is about 50 kb long, and two mRNA transcripts can arise through alternative splicing: one generates the type I transmembrane protein (130 kDa), the other is assumed to generate a secreted protein (70 kDa). Transmembrane Klotho protein is expressed mainly in choroid plexus epithelial cells of the brain and the distal convoluted tubules of the kidney. The extracellular region of transmembrane Klotho protein can be cleaved by α- and β-secretases, and eventually finds its way into blood, urine, and cerebrospinal fluid. This cleaved Klotho protein is commonly known as the soluble Klotho (sKlotho) (6, 7). Previous studies have mainly focused on anti-aging functions, such as cell survival, proliferation, and apoptosis (8). In recent years, it has also been found to be involved in the regulation of energy metabolism. As the concentration of sKlotho increased, it exerted a protective effect on renal endothelial cells (9, 10). However, in the early stage of DN in patients with normal renal function, the change in sKlotho remains controversial (11–15). Therefore, this study aimed to investigate the relationship between the sKlotho levels and DN, especially its relationship with the early stage of DN to guide clinical treatment and prognosis.

METHODS

Search

We searched the following electronic databases: Web of Science, Embase, PubMed, Google Scholar, and China National Knowledge Infrastructure (CNKI). The following search terms were used for the title or abstract: “diabetic kidney disease” OR “diabetic nephropathy” in combination with the term “Klotho.” The retrieval time was limited to 1980–2020, and the language was limited to English and Chinese. We also checked the references of the retrieved articles to avoid missing additional eligible studies. We did not search for any unpublished studies. The registration number for the systematic review and meta-analysis was CRD 4202309103 in PROSPERO. A complete list of the preferred reporting items for systematic reviews and meta-analyses is provided in the Supplementary Data (S1).

Inclusion Criteria

The studies included in this meta-analysis met the following criteria: (1) detailed data about the sKlotho levels in patients with diabetes and DN; (2) patients with different stages of DN; and (3) multiple studies of the same author and department; only the study with the largest sample size was selected.

The degree of DN was based on the urine albumin-creatinine ratio (UACR) and chronic kidney disease-Kidney Disease Outcomes Quality Initiative (KD-DOQI) criteria. Patients with diabetes were categorized into three groups according to the UACR: UACR < 30 mg/g creatinine (normalalbuminuria), UACR 30–299 mg/g creatinine (microalbuminuria), and UACR ≥ 300 mg/g creatinine (macroalbuminuria). The early stage of DN was defined as microalbuminuria or CKD stage 1–2.

Data Extraction and Risk of Bias

Two reviewers independently searched according to the search strategy and independently read the title and abstract according to the search results for preliminary screening to exclude the study that did not meet the inclusion criteria. The full text of the papers were analyzed to determine whether they meet the inclusion criteria. Two reviewers can contact and crosscheck the author if the information is incomplete. If the conclusions of the two evaluators were not consistent, the differences were resolved through discussion. If the discussion failed to resolve the differences, it was judged and arbitrated by a third researcher. The Newcastle-Ottawa Scale (NOS) is a risk of a bias assessment tool for observational studies recommended by the Cochrane Collaboration (16, 17). The quality of the included studies was evaluated according to the NOS. The NOS includes three aspects: the selection method of the case and control groups, comparability of the case and control groups, and evaluation method of exposure. The NOS ranged from zero to nine stars, and quality was based on star scores.

Statistical Analysis

The data were expressed as standardized mean differences (SMD) and 95% confidence intervals (CIs). Heterogeneity among the included studies was assessed using the I² statistic. If I² was < 50%, the heterogeneity among studies was low or moderate, and the fixed-effect model was adopted. Otherwise, if I² was > 50%, the random-effects model was used for analysis. Sensitivity analysis was performed to judge the stability of the results. The Begg’s and Egger’s tests were used to identify publication bias. Statistical significance was set at P < 0.05. Data were analyzed using Stata version 12.0 (College Station, TX, USA).

RESULTS

A total of 329 studies were retrieved from the databases. After screening, 14 articles were selected (11–14, 18–27). The flow
Results of the Meta-Analysis

The sKlotho level in patients with DN was significantly lower than that in patients with diabetes (SMD: -1.52, 95% CI [-2.24, -0.80]). Forest plots of the sKlotho levels in patients with DN compared to those with diabetes are presented in Figure 2. Moreover, there was a significant difference in the sKlotho levels between patients with diabetes without DN and those with early stage of DN (SMD: -1.65, 95% CI [-2.60, -0.70]). Forest plots of the sKlotho levels are shown in Figure 3. Compared with the controls, the sKlotho level was also significantly lower in patients with diabetes (SMD: -2.12, 95% CI [-4.14, -1.10], Figure 4).

Sensitivity Analysis and Publication Bias

Sensitivity analysis was performed to examine the influence of each study. We found no significant difference between the sensitivity analysis results and our previous estimates, indicating that the data of a single study had a little overall impact. Thus, it can be inferred that the results of this meta-analysis were stable. (Figures S1-S3). A careful and comprehensive search was performed for articles obtained from the database. In addition, the Begg’s and Egger’s tests were performed to determine whether there was a potential publication bias in the reviewed study. The results (P > 0.05) indicated no publication bias.

DISCUSSION

This systematic review was the first to evaluate the relationship between the sKlotho levels and DN in patients with diabetes. Although some studies have shown that the sKlotho levels of patients with DN are lower than those without DN, in the early stage of patients with DN with normal renal function and albuminuria, the change in sKlotho is still controversial. Fourteen independent studies were included in the meta-analysis. We concluded that the sKlotho level in patients with DN was significantly lower than that in patients without DN (SMD: -1.52, 95% CI [-2.24, -0.80]), and it was also significantly lower in the early stages of DN (SMD: -1.65, 95% CI [-2.60, -0.70]).

Diabetic nephropathy is characterized by changes in the structure and function of the glomeruli. The disease is reversible at an early stage and irreversible in patients with persistent proteinuria. The International Diabetes Federation predicts that by 2030, the total number of patients with type 2 diabetes will reach 439 million worldwide (28). The incidence of diabetes-related complications is also increasing with an increase in the number of patients with diabetes. Identifying serum biomarkers for the early diagnosis of DN is of great significance for improving the prognosis of patients with diabetes. Determination of renal function is an important means of diagnosing DN (29). However, there are still some changes in renal function indices in some patients. In recent years, the role of Klotho in diabetes and kidney disease has attracted increasing attention (30).

Klotho protein is a transmembrane protein and mainly expressed in the kidney, heart, and brain and can inhibit the inflammatory response (31). It protects islet β-cell function and can promote insulin secretion, thereby reducing blood glucose and delaying the process of renal disease (Figure 5) (32). Supplementing exogenous α-Klotho can reduce hyperglycemia injury by promoting glycogen storage, inhibiting gluconeogenesis, improving insulin sensitivity in type 2 diabetes, anti-inflammatory, antioxidant stress, and inhibiting fibrosis; thus, protecting the kidney (33–35).
TABLE 1 | Study characteristics of the published studies included in the meta-analysis.

| Author          | Publication Year | Study Period               | Region      | Study Design      | Study Sample                                                                 | Sex                                                                 | Age                                                                 | Details                                                                 | NOS |
|-----------------|------------------|-----------------------------|-------------|-------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------|-----|
| Kacso IM        | 2012             | –                           | Romania     | Case-control study| 146 patients with type 2 diabetes and 43 healthy controls                      | patients with type 2 diabetes: mean age 63.38 ± 12.20 years; healthy controls: mean age 61.07 ± 11.47 years. |                                                                  | The diabetic patients were categorized into 3 groups according to UACR. The mean duration of diabetes was 8.8 ± 5.6 years. | 5   |
| Lee EY          | 2014             | February 2010 - February 2012| Korea       | Case-control study| 147 patients with type 2 diabetes and 43 healthy controls                      | patients with type 2 diabetes: mean age 56.6 ± 10.6 years; healthy controls: mean age 50.9 ± 7.8 years. |                                                                  | The diabetic patients were categorized into 3 groups according to UACR. The mean duration of diabetes was 7.8 ± 5.9 years. | 6   |
| Wu C            | 2014             | April 2010 - July 2013      | China       | Case-control study| 462 patients with type 2 diabetes and 160 healthy controls                     | patients with type 2 diabetes: mean age 52.9 ± 6.3 years; healthy controls: mean age 51.8 ± 6.5 years. |                                                                  | The diabetic patients were categorized into 3 groups according to UACR. The mean duration of diabetes was 7.7 ± 4.2 years. | 7   |
| Dogan B         | 2016             | February 2012 - March 2013  | Turkey      | Case-control study| 147 patients with type 1 diabetes and 76 healthy controls                     | patients with type 1 diabetes: mean age 34.1 ± 9.2 years; healthy controls: mean age 33.9 ± 9.1 years.  |                                                                  | The diabetic patients were categorized into 3 groups according to UACR. | 7   |
| Inci A          | 2016             | January 2014 - June 2014    | Turkey      | Case-control study| 109 patients with type 2 diabetes and 32 healthy controls                     | patients with type 2 diabetes: mean age 61.63 ± 9.77 years; healthy controls: mean age 49.53 ± 7.32 years. |                                                                  | The diabetic patients were categorized into 3 groups according to UACR. | 7   |
| Malteze G       | 2017             | –                           | London      | Observational study| 78 patients with type 1 diabetes                                               | patients with microalbuminuria: mean age 54.4 ± 11.6 years; healthy controls: mean age 43.3 ± 9.6 years. |                                                                  | The diabetic patients were categorized into 2 groups according to UACR. The mean duration of diabetes was 30.9 ± 10.0 years. | 5   |
| Nie F           | 2017             | 2014 - 2016                 | China       | Observational study| 96 patients with type 2 diabetes, 90 patients with diabetic nephropathy and 106 healthy controls | patients with type 2 diabetes: mean age 52.85 ± 11.15 years; healthy controls: mean age 52.47 ± 12.15 years. |                                                                  | The diabetic patients were categorized into 3 groups according to UACR. | 6   |
| Ye M            | 2017             | June 2016 - January 2017    | China       | Case-control study| 160 patients with type 2 diabetes and 80 healthy controls                     | patients with type 2 diabetes: mean age 52.85 ± 11.15 years; healthy controls: mean age 52.47 ± 12.15 years. |                                                                  | All the patients were newly diagnosed and categorized into 2 groups according to UACR. | 6   |
| Fountoulakis N  | 2018             | 2004-2006                   | London      | Observational study| 101 patients with type 2 diabetes                                             | patients with type 2 diabetes: mean age (range) was 60 (40-82) years.                                          |                                                                  | The mean duration of diabetes was 9.8 ± 6.6 years, with a mean eGFR of 90.4 ± 20.0 ml/min. The diabetic patients were categorized into 2 groups according to UACR. | 8   |
| Zhang L         | 2018             | January 2016 -              | China       | Case-control study| 127 patients with type 2 diabetes                                             | patients with type 2 diabetes: 52.5 (41- |                                                                  | –                                                                          | 7   |

(Continued)
| Author | Publication Year | Study Period | Region | Study Design | Study Sample | Sex | Age Details | NOS |
|--------|------------------|--------------|--------|--------------|--------------|-----|-------------|-----|
| Li Q (24) | 2019 | February 2017 - September 2017 | China | Case-control study | 68 patients with type 2 diabetes and 22 healthy controls | diabetes; 59 males; patients with diabetic nephropathy: 55 males; healthy controls: 77 males | patients with type 2 diabetes: mean age 48.1 ± 6.3 years; healthy controls: mean age 45.5 ± 4.2 years. | 6 |
| Chen J (25) | 2020 | February 2015 - August 2018 | China | Case-control study | 160 patients with type 2 diabetes and 60 healthy controls | diabetes; 70 males; patients with diabetic nephropathy: 60 males; healthy controls: 30 males. | patients with type 2 diabetes: mean age 57.8 ± 5.6 years; healthy controls mean age 50.2 ± 6.9 years. | 7 |
| Tian Q (26) | 2020 | November 2016 - November 2018 | China | Case-control study | 174 patients with type 2 diabetes and 55 healthy controls | diabetes; 70 males; patients with diabetic nephropathy: 58 males; healthy controls: 47 males. | patients with type 2 diabetes: mean age 58.0 ± 7.9 years; healthy controls: mean age 56.1 ± 7.4 years. | 6 |
| Nie L (27) | 2021 | February 2017 - May 2018 | China | Case-control study | 80 patients with type 2 diabetes and 50 healthy controls | diabetes; 36 males; patients with diabetic nephropathy: 32 males; healthy controls: 22 males. | patients with type 2 diabetes: mean age 58.6 ± 5.58 years; healthy controls: mean age 58.27 ± 5.35 years. | 5 |

NOS, Newcastle-Ottawa Scale; UACR, urine albumin-creatinine ratio.

**FIGURE 2** | Forest plots and funnel plots of sKlotho level in patients with diabetic nephropathy compared to diabetes. Diamond represents the pooled SMDs at 95% CI. SMD, standardized mean difference; CI, confidence interval.
Klotho attenuates diabetic nephropathy in db/db mice and ameliorates high glucose-induced injury of human renal glomerular endothelial cells (36). In addition, Klotho can inhibit the renin-angiotensin-aldosterone system, and the nuclear factor kappa B (NF-κB) signaling pathway inhibits renal fibrosis caused by the inflammatory response. Therefore, the consumption of Klotho in patients with DN is relatively high, resulting in a decrease in the Klotho levels (37, 38). Animal experiments have shown that mice lacking the Klotho gene show significant changes, such as endothelial cell injury and abnormal energy metabolism. After sKlotho supplementation, the expression of nitric oxide in vascular endothelial cells increases, reverses vascular inflammatory reactions, and protects renal function (39). Exogenous Klotho attenuates high glucose (HG)-induced pro-fibrotic genes, TGF-β signaling and cell hypertrophy in rat renal interstitial fibroblasts (NRK-49F) cells. Moreover, Klotho attenuates HG-induced fibronectin expression and cell hypertrophy via the ERK1/2 and p38 kinase-dependent pathways (40). Klotho protein overexpression attenuates renal hypertrophy and glomerular injury in this mouse model of diabetic nephropathy. Klotho overexpression attenuated renal hypertrophy, albuminuria, glomerular mesangial expansion, and endothelial glyocalyx loss in the AKITA mice (41). In our meta-analysis, we found that even in the early stages of DN, the sKlotho level was significantly lower in patients with diabetes without DN. We hope that sKlotho is a more sensitive biomarker during the early stages of DN.

This meta-analysis aimed to statistically evaluate the sKlotho levels in patients with DN. However, this study had some limitations. In different studies, the duration of diabetes and severity of the disease were variant. Meanwhile, the overall...
quality of the studies was not high. All of these factors may have affected the results; therefore, the findings of this meta-analysis should be interpreted cautiously, as further research is needed.

CONCLUSION

This systematic review was the first to evaluate the relationship between the sKlotho levels and DN. The sKlotho level was significantly lower in the early stages of DN, indicating that sKlotho might be a new biomarker of DN in the future.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

TG designed the study. CX searched databases and collected the data. XS and ZL assessed the quality of the study. XS performed the analysis. TG and CX wrote the manuscript. All authors contributed to this systematic review and meta-analysis. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.cn) for English language editing.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.902765/full#supplementary-material

REFERENCES

1. Sagoo MK, Gnudi L. Diabetic Nephropathy: An Overview. *Methods Mol Biol* (2020) 2067:3–7. doi: 10.1007/978-1-4939-9841-8_1
2. Guo J, Zheng HJ, Zhang W, Lou W, Xia C, Han XT, et al. Accelerated Kidney Aging in Diabetes Mellitus. *Oxid Med Cell Longev* (2020), 1234059. doi: 10.1155/2020/1234059
3. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Tatma T, et al. Macrovacular Complications of Type 2 Diabetes Mellitus. *Curr Vasc Pharmacol* (2020) 18(2):110–16. doi: 10.2174/1570161117666190405165151
4. Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic Nephropathy: Diagnosis and Treatment. *Nat Rev Endocrinol* (2013) 9(12):713–23. doi: 10.1038/nrendo.2013.184
5. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the Mouse Klotho Gene Leads to a Syndrome Resembling Ageing. *Nature* (1997) 390(6655):45–51. doi: 10.1038/36285
6. Xu Y, Sun Z. Molecular Basis of Klotho: From Gene to Function in Aging. *Endocr Rev* (2015) 36(2):174–93. doi: 10.1210/er.2013-1079
7. Dalton GD, Xie J, An SW, Huang CL. New Insights Into the Mechanism of Action of Klotho. *Front Endocrinol* (2017) 8:1e10. doi: 10.3389/fendo.2017.00323
14. Inci A, Sari F, Coban M, Olmaz R, Dolu S, Sarıkläy M, et al. Fibroblast Klotho Levels in CKD and Relationship to Progression. *Am J Kidney Dis* (2013) 61:989.e909. doi: 10.1053/ajkd.2013.01.024

15. Marlena T, Aguieszka P. Antiinflammatory Actions of Klotho: Implications for Therapy of Diabetic Nephropathy. *Int J Mol Sci* (2021) 22(2):956. doi: 10.3390/ijms22020956

16. Kacso IM, Bondor CI, Kacso G. Soluble Serum Klotho in Diabetic Nephropathy: Relationship to VEGF-A. *Clin Biochem* (2012) 45(16-17):1415–20. doi: 10.1016/j.clinbiochem.2012.07.098

17. Wu C, Wang Q, Lv C, Qin N, Lei S, Yuan Q, et al. The Changes of Serum Klotho and NGAL Levels and Their Correlation in Type 2 Diabetes Mellitus Patients With Different Stages of Urinary Albumin. *Diabetes Res Clin Pr* (2014) 106(2):343–50. doi: 10.1016/j.diabres.2014.08.026

18. Dogan B, Arikam IH, Guler D, Keles N, Isbilen B, Isman F, et al. Fibroblast Growth Factor-23 But Not Klotho Levels Are Related to Diastolic Dysfunction in Type 1 Diabetic Patients With Early Diabetic Nephropathy. *Int Urol Nephrol* (2016) 48(3):399–407. doi: 10.1007/s11255-015-1190-y

19. Inci A, Sari F, Coban M, Olmaz R, Dolo S, Sarıkläy M, et al. Soluble Klotho and Fibroblast Growth Factor 23 Levels in Diabetic Nephropathy With Different Stages of Albuminuria. *J Invest Med* (2016) 64(6):1128–33. doi: 10.1136/jim-2016-000142

20. Furia-Basulso A, Martinez-Ramirez HR, Gómez-Garcia EF, Cueto-Manzano AM, Cortés-Sanabria L, Hernández-Ramos LE, et al. Circulating Levels of Soluble Klotho and Fibroblast Growth Factor 23 in Diabetic Patients and Its Association With Early Nephropathy. *Arch Respir Med* (2018) 49(7):451–5. doi: 10.1016/j.arcmed.2019.01.008

21. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non Randomised Studies in Meta-Analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed 2014 Aug 5).

22. Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*. Available at: http://www.cochrane-handbook.org (Accessed 2014 Aug).

23. Lee EY, Kim SS, Kim JI, Song SH, Cha SK, et al. Soluble Alpha-Klotho as a Novel Biomarker in the Early Stage of Nephropathy in Patients With Type 2 Diabetes. *PLoS One* (2014) 9(8):e102984. doi: 10.1371/journal.pone.0102984

24. Malese G, Fountoulakis N, Siow RC, Gnudi L, Karaliiedjie J, Perturbations of the Anti-Aging Hormone Klotho in Patients With Type 1 Diabetes and Microalbuminuria. *Diabetologia* (2017) 60(5):911–4. doi: 10.1007/s00125-017-4219-1

25. Nie F, Wu D, Du H, Yang X, Yang M, Pang X, et al. Serum Klotho Protein Levels and Their Correlations With the Progression of Type 2 Diabetes Mellitus. *J Diabetes Complications* (2017) 31(3):394–8. doi: 10.1016/j.jdiacomp.2016.11.008

26. Ye M, Yang Y, Cao J. The Relationships of Serum Klotho Protein With Vascular Endothelial Growth Factor and Urinary Albumin Creatinine Ratio in Patients With Early Diabetic Nephropathy. *J Med Theor Prac* (2017) 30(18):2673–5. doi: 10.19381/j.issn.1001-7585.2017.18.005

27. Fountoulakis N, Maltese G, Gnudi L, Karaliiedjie J. Reduced Levels of Anti-Aging Hormone Klotho Predict Renal Function Decline in Type 2 Diabetes. *J Clin Endocrinol Metab* (2018) 103(5):2026–32. doi: 10.1210/jc.2018-00004

28. Zhang L, Liu H. Clinical Implication of Alterations in Serum Klotho Levels in Patients With Type 2 Diabetes Mellitus and Its Associated Complications. *J Diabetes Complications* (2018) 32(10):922–30. doi: 10.1016/j.jdiacomp.2018.06.002

29. Li Q, Wang Z, Chu Y. Relationship Between Proteinuria, Serum TGF-B1, and Klotho Protein in Patients With Type 2 Diabetic Nephropathy. *J Hubei Minzu Univ (Medical Edition)* (2019) 36(01):25–7. doi: 10.13350/j.cnki.42-1590/r.2019.01.007

30. Chen J. Correlation Between Cystatin C, α-Klotho Protein, sCAM-1 and Diabetic Nephropathy. *Lab Med* (2020) 35(10):1032–5. doi: 10.3969/j.issn.1673-8640.2020.10.015

31. Tian Q, Li B, Li N, Guo S, Zhang M, Li J, et al. Changes and Significance of Serum Pentraxin 3 and α-Klotho Protein Levels in Patients With Type 2 Diabetic Kidney Disease. *Anhui Med J* (2020) 41(08):900–6. doi: 10.3969/j.issn.1000-0399.2020.08.010

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.